7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      ORF10–Cullin-2–ZYG11B complex is not required for SARS-CoV-2 infection

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Understanding the functions of the genes encoded in the SARS-CoV-2 genome is imperative to understanding its pathogenesis. One unique feature of the SARS-CoV-2 genome is ORF10, a small putative protein that was hypothesized to promote infection by hijacking a cellular E3 ubiquitin ligase, CRL2 ZYG11B. Here, we investigate whether ORF10 hijacks CRL2 ZYG11B or functions in other ways, such as to inhibit CRL2 ZYG11B or be degraded by it. We do not find evidence that ORF10 regulates or is regulated by CRL2 ZYG11B, and, furthermore, we find that ZYG11B and its paralog are dispensable for SARS-CoV-2 infection in cultured cells.

          Abstract

          In order to understand the transmission and virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is necessary to understand the functions of each of the gene products encoded in the viral genome. One feature of the SARS-CoV-2 genome that is not present in related, common coronaviruses is ORF10, a putative 38-amino acid protein-coding gene. Proteomic studies found that ORF10 binds to an E3 ubiquitin ligase containing Cullin-2, Rbx1, Elongin B, Elongin C, and ZYG11B (CRL2 ZYG11B). Since CRL2 ZYG11B mediates protein degradation, one possible role for ORF10 is to “hijack” CRL2 ZYG11B in order to target cellular, antiviral proteins for ubiquitylation and subsequent proteasomal degradation. Here, we investigated whether ORF10 hijacks CRL2 ZYG11B or functions in other ways, for example, as an inhibitor or substrate of CRL2 ZYG11B. While we confirm the ORF10−ZYG11B interaction and show that the N terminus of ORF10 is critical for it, we find no evidence that ORF10 is functioning to inhibit or hijack CRL2 ZYG11B. Furthermore, ZYG11B and its paralog ZER1 are dispensable for SARS-CoV-2 infection in cultured cells. We conclude that the interaction between ORF10 and CRL2 ZYG11B is not relevant for SARS-CoV-2 infection in vitro.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

            SUMMARY The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Improved vectors and genome-wide libraries for CRISPR screening.

                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                27 April 2021
                07 April 2021
                07 April 2021
                : 118
                : 17
                : e2023157118
                Affiliations
                [1] aDivision of Genetics, Department of Genetics, Brigham and Women’s Hospital, Harvard Medical School , Boston, MA 02115;
                [2] bHoward Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA 02115;
                [3] cDepartment of Microbiology, National Emerging Infectious Disease Laboratories, Boston University Medical Campus , Boston, MA 02118;
                [4] dDepartment of Cell Biology, Blavatnik Institute, Harvard Medical School , Boston, MA 02115;
                [5] eDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine , New York, NY 10016;
                [6] fHoward Hughes Medical Institute, New York University Grossman School of Medicine , New York, NY 10016;
                [7] gProteomics Laboratory, Division of Advanced Research Technologies, New York University Grossman School of Medicine , New York, NY 10016;
                [8] hDepartment of Neurology, New York University Grossman School of Medicine , New York, NY 10016
                Author notes

                Contributed by Stephen J. Elledge, February 9, 2021 (sent for review November 5, 2020; reviewed by Eugene Oh and Mike Tyers)

                Author contributions: E.L.M., C.J.D., L.P.V., J.L., G.R., M.P., J.W.H., R.A.D., and S.J.E. designed research; E.L.M., C.J.D., L.P.V., J.L., G.R., C.O., L.L., B.M.-M., J.A.P., A.D., and B.U. performed research; G.R. contributed new reagents/analytic tools; E.L.M., C.J.D., L.P.V., J.L., G.R., C.O., A.D., B.U., M.P., and R.A.D. analyzed data; and E.L.M., L.P.V., J.L., M.P., J.W.H., R.A.D., and S.J.E. wrote the paper.

                Reviewers: E.O., Massachusetts General Hospital; and M.T., University of Montreal.

                1C.J.D., L.P.V., and J.L. contributed equally to this work.

                Author information
                https://orcid.org/0000-0001-9980-9018
                https://orcid.org/0000-0002-4284-2914
                https://orcid.org/0000-0003-2400-9790
                https://orcid.org/0000-0003-3222-7261
                https://orcid.org/0000-0001-6164-1299
                https://orcid.org/0000-0003-1725-2020
                https://orcid.org/0000-0002-4291-413X
                https://orcid.org/0000-0002-6944-7236
                https://orcid.org/0000-0001-7923-6283
                Article
                202023157
                10.1073/pnas.2023157118
                8092598
                33827988
                686b0b96-eda7-4846-a7c1-16225f2dc9bf
                Copyright © 2021 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

                History
                Page count
                Pages: 8
                Funding
                Funded by: HHS | National Institutes of Health (NIH) 100000002
                Award ID: GM132129
                Award Recipient : Laura Pontano Vaites Award Recipient : Steven P. Gygi Award Recipient : Michele Pagano Award Recipient : J. Wade Harper Award Recipient : Stephen J. Elledge
                Funded by: MassCPR
                Award ID: No number
                Award Recipient : ELIJAH Mena Award Recipient : Colin O'Leary Award Recipient : Robert Davey Award Recipient : Stephen J. Elledge
                Funded by: HHS | National Institutes of Health (NIH) 100000002
                Award ID: AG11085
                Award Recipient : Laura Pontano Vaites Award Recipient : Steven P. Gygi Award Recipient : Michele Pagano Award Recipient : J. Wade Harper Award Recipient : Stephen J. Elledge
                Funded by: HHS | NIH | National Cancer Institute (NCI) 100000054
                Award ID: P30CA016087
                Award Recipient : Michele Pagano
                Categories
                423
                530
                Biological Sciences
                Microbiology
                Custom metadata
                free

                sars-cov-2,orf10,zyg11b,zer1,cul2
                sars-cov-2, orf10, zyg11b, zer1, cul2

                Comments

                Comment on this article